252 related articles for article (PubMed ID: 23386691)
1. Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery.
Shen H; Rodriguez-Aguayo C; Xu R; Gonzalez-Villasana V; Mai J; Huang Y; Zhang G; Guo X; Bai L; Qin G; Deng X; Li Q; Erm DR; Aslan B; Liu X; Sakamoto J; Chavez-Reyes A; Han HD; Sood AK; Ferrari M; Lopez-Berestein G
Clin Cancer Res; 2013 Apr; 19(7):1806-15. PubMed ID: 23386691
[TBL] [Abstract][Full Text] [Related]
2. Sustained small interfering RNA delivery by mesoporous silicon particles.
Tanaka T; Mangala LS; Vivas-Mejia PE; Nieves-Alicea R; Mann AP; Mora E; Han HD; Shahzad MM; Liu X; Bhavane R; Gu J; Fakhoury JR; Chiappini C; Lu C; Matsuo K; Godin B; Stone RL; Nick AM; Lopez-Berestein G; Sood AK; Ferrari M
Cancer Res; 2010 May; 70(9):3687-96. PubMed ID: 20430760
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery.
Landen CN; Chavez-Reyes A; Bucana C; Schmandt R; Deavers MT; Lopez-Berestein G; Sood AK
Cancer Res; 2005 Aug; 65(15):6910-8. PubMed ID: 16061675
[TBL] [Abstract][Full Text] [Related]
4. Dual targeting of EphA2 and FAK in ovarian carcinoma.
Shahzad MM; Lu C; Lee JW; Stone RL; Mitra R; Mangala LS; Lu Y; Baggerly KA; Danes CG; Nick AM; Halder J; Kim HS; Vivas-Mejia P; Landen CN; Lopez-Berestein G; Coleman RL; Sood AK
Cancer Biol Ther; 2009 Jun; 8(11):1027-34. PubMed ID: 19395869
[TBL] [Abstract][Full Text] [Related]
5. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth.
Merritt WM; Lin YG; Spannuth WA; Fletcher MS; Kamat AA; Han LY; Landen CN; Jennings N; De Geest K; Langley RR; Villares G; Sanguino A; Lutgendorf SK; Lopez-Berestein G; Bar-Eli MM; Sood AK
J Natl Cancer Inst; 2008 Mar; 100(5):359-72. PubMed ID: 18314475
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment.
Nishimura M; Jung EJ; Shah MY; Lu C; Spizzo R; Shimizu M; Han HD; Ivan C; Rossi S; Zhang X; Nicoloso MS; Wu SY; Almeida MI; Bottsford-Miller J; Pecot CV; Zand B; Matsuo K; Shahzad MM; Jennings NB; Rodriguez-Aguayo C; Lopez-Berestein G; Sood AK; Calin GA
Cancer Discov; 2013 Nov; 3(11):1302-15. PubMed ID: 24002999
[TBL] [Abstract][Full Text] [Related]
7. Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer.
Yang X; Iyer AK; Singh A; Milane L; Choy E; Hornicek FJ; Amiji MM; Duan Z
Pharm Res; 2015 Jun; 32(6):2097-109. PubMed ID: 25515492
[TBL] [Abstract][Full Text] [Related]
8. Mesoporous silicon particles for sustained gene silencing.
Hasan N; Mann A; Ferrari M; Tanaka T
Methods Mol Biol; 2013; 1049():481-93. PubMed ID: 23913239
[TBL] [Abstract][Full Text] [Related]
9. Cosilencing of PKM-2 and MDR-1 Sensitizes Multidrug-Resistant Ovarian Cancer Cells to Paclitaxel in a Murine Model of Ovarian Cancer.
Talekar M; Ouyang Q; Goldberg MS; Amiji MM
Mol Cancer Ther; 2015 Jul; 14(7):1521-31. PubMed ID: 25964202
[TBL] [Abstract][Full Text] [Related]
10. MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer.
Yang X; Iyer AK; Singh A; Choy E; Hornicek FJ; Amiji MM; Duan Z
Sci Rep; 2015 Feb; 5():8509. PubMed ID: 25687880
[TBL] [Abstract][Full Text] [Related]
11. Silencing of EphA2 inhibits invasion of human gastric cancer SGC-7901 cells in vitro and in vivo.
Yuan W; Chen Z; Chen Z; Wu S; Guo J; Ge J; Yang P; Huang J
Neoplasma; 2012; 59(1):105-13. PubMed ID: 22103904
[TBL] [Abstract][Full Text] [Related]
12. EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma.
Lee JW; Han HD; Shahzad MM; Kim SW; Mangala LS; Nick AM; Lu C; Langley RR; Schmandt R; Kim HS; Mao S; Gooya J; Fazenbaker C; Jackson D; Tice DA; Landen CN; Coleman RL; Sood AK
J Natl Cancer Inst; 2009 Sep; 101(17):1193-205. PubMed ID: 19641174
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
Landen CN; Lu C; Han LY; Coffman KT; Bruckheimer E; Halder J; Mangala LS; Merritt WM; Lin YG; Gao C; Schmandt R; Kamat AA; Li Y; Thaker P; Gershenson DM; Parikh NU; Gallick GE; Kinch MS; Sood AK
J Natl Cancer Inst; 2006 Nov; 98(21):1558-70. PubMed ID: 17077358
[TBL] [Abstract][Full Text] [Related]
14. Liposomal siRNA for ovarian cancer.
Mangala LS; Han HD; Lopez-Berestein G; Sood AK
Methods Mol Biol; 2009; 555():29-42. PubMed ID: 19495686
[TBL] [Abstract][Full Text] [Related]
15. Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer.
Kim GH; Won JE; Byeon Y; Kim MG; Wi TI; Lee JM; Park YY; Lee JW; Kang TH; Jung ID; Shin BC; Ahn HJ; Lee YJ; Sood AK; Han HD; Park YM
Drug Deliv; 2018 Nov; 25(1):1394-1402. PubMed ID: 29890852
[TBL] [Abstract][Full Text] [Related]
16. CD44-Targeting PLGA Nanoparticles Incorporating Paclitaxel and FAK siRNA Overcome Chemoresistance in Epithelial Ovarian Cancer.
Byeon Y; Lee JW; Choi WS; Won JE; Kim GH; Kim MG; Wi TI; Lee JM; Kang TH; Jung ID; Cho YJ; Ahn HJ; Shin BC; Lee YJ; Sood AK; Han HD; Park YM
Cancer Res; 2018 Nov; 78(21):6247-6256. PubMed ID: 30115698
[TBL] [Abstract][Full Text] [Related]
17. Functional roles of Src and Fgr in ovarian carcinoma.
Kim HS; Han HD; Armaiz-Pena GN; Stone RL; Nam EJ; Lee JW; Shahzad MM; Nick AM; Lee SJ; Roh JW; Nishimura M; Mangala LS; Bottsford-Miller J; Gallick GE; Lopez-Berestein G; Sood AK
Clin Cancer Res; 2011 Apr; 17(7):1713-21. PubMed ID: 21300758
[TBL] [Abstract][Full Text] [Related]
18. Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer.
Landen CN; Merritt WM; Mangala LS; Sanguino AM; Bucana C; Lu C; Lin YG; Han LY; Kamat AA; Schmandt R; Coleman RL; Gershenson DM; Lopez-Berestein G; Sood AK
Cancer Biol Ther; 2006 Dec; 5(12):1708-13. PubMed ID: 17106249
[TBL] [Abstract][Full Text] [Related]
19. Metronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer.
Gharpure KM; Chu KS; Bowerman CJ; Miyake T; Pradeep S; Mangala SL; Han HD; Rupaimoole R; Armaiz-Pena GN; Rahhal TB; Wu SY; Luft JC; Napier ME; Lopez-Berestein G; DeSimone JM; Sood AK
Mol Cancer Ther; 2014 Jul; 13(7):1750-7. PubMed ID: 24755199
[TBL] [Abstract][Full Text] [Related]
20. Nanoparticle delivery of siRNA against TWIST to reduce drug resistance and tumor growth in ovarian cancer models.
Roberts CM; Shahin SA; Wen W; Finlay JB; Dong J; Wang R; Dellinger TH; Zink JI; Tamanoi F; Glackin CA
Nanomedicine; 2017 Apr; 13(3):965-976. PubMed ID: 27890656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
